


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) Indol derivatives according to Formula (I)



a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein

$-a^1=a^2-a^3=a^4-$ is a bivalent radical of formula

$-N=CH-CH=CH-$ (a-1),

$-CH=N-CH=CH-$ (a-2),

$-CH=CH-N=CH-$ (a-3) or

$-CH=CH-CH=N-$ (a-4) ;

$-Z^1-Z^2-$ is a bivalent radical of formula

$-O-CH_2-O-$ (b-1),

$-O-CH_2-CH_2-O-$ (b-2),

$-NR^7-CH_2-CH_2-O-$ (b-3),

$-O-CH_2-CH_2-NR^7-$ (b-4),

$-NR^7-CH_2-CH_2-NR^7-$ (b-5) or

$-S-CH_2-CH_2-O-$ (b-6) ;

wherein R^7 is selected from the group consisting of hydrogen, hydroxy, alkyl, alkyloxyalkyl and alkylcarbonyl ;

X is CR^6 or N ;


each R^1 , R^2 , R^3 , R^4 and R^6 is independently from each other selected from the group consisting of hydrogen, halo, cyano, nitro, alkyl, alkenyl, mono- or dialkylaminoalkyl, hydroxy, alkyloxy, alkylcarbonyloxy, amino, mono- or dialkylamino, formylamino,

alkylcarbonylamino, alkylsulfonylamino, hydroxycarbonyl, alkyloxycarbonyl, aminocarbonyl, mono- or dialkylaminocarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, alkylthio, aryl and heteroaryl ;

p is an integer equal to 0, 1, 2 or 3 ;

R⁵ is hydrogen or alkyl ;

Y is a bivalent radical of formula



wherein

m is an integer equal to 0 or 1 ;

n is an integer equal to 0, 1, 2, 3, 4, 5 or 6 ;

the dotted line represents an optional double bond ;

R⁸ is selected from the group consisting of hydrogen, halo, alkyl, hydroxy, alkyloxy, alkylcarbonyloxy, alkyloxycarbonyloxy, hydroxycarbonyl, aminocarbonyl, mono- or dialkylaminocarbonyl, alkyloxycarbonyl and amino;

alkyl represents a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; said radical being optionally substituted with one or more phenyl, halo, cyano, oxo, hydroxy, formyl or amino radicals ;

alkenyl represents a straight or branched unsaturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic unsaturated hydrocarbon radical having from 3 to 6 carbon atoms ; said radical having one or more double bonds and said radical being optionally substituted with one or more phenyl, halo, cyano, oxo, hydroxy, formyl or amino radicals ;

aryl represents phenyl or naphthyl, optionally substituted with one or more radicals selected from the group consisting of alkyl, halo, cyano, oxo, hydroxy, alkyloxy and amino ; and

heteroaryl represents a monocyclic heterocyclic radical selected from the group consisting of azetidiny, pyrrolidiny, dioxoly, imidazolidiny, pyrrazolidiny, piperidiny, homopiperidiny, dioxyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, imidazolidiny, tetrahydrofuranyl, 2H-pyrrolyl, pyrroliny, imidazoliny, pyrrazoliny, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, pyridiny, pyrimidiny, pyraziny, pyridaziny and triaziny ; each radical optionally substituted with one or more radicals selected from the group consisting of alkyl, aryl, arylalkyl, halo, cyano, oxo, hydroxy, alkyloxy and amino;

with the proviso with the proviso that compounds wherein simultaneously $-a^1=a^2-a^3=a^4-$ is (a-4), $-Z^1-Z^2-$ is (b-2) and Y is (c-2) are excluded.


2. (Original) Compound according to claim 1, characterized in that $-a^1=a^2-a^3=a^4-$ is a bivalent radical of formula (a-3) or (a-4).
3. (Currently Amended) Compound according to claim 1, wherein ~~any one of claims 1 and 2, characterized in that~~ $-Z^1-Z^2-$ is a bivalent radical of formula (b-1), (b-2) or (b-3) wherein R^7 is hydrogen or methyl.
4. (Currently Amended) Compound according to claim 1, wherein ~~any one of claims 1 to 3, characterized in that~~ Y is a bivalent radical of formula (c-1) wherein $n = 3$ or (c-2) wherein $m = 0$ or 1 and R^8 is hydrogen.
5. (Currently Amended) Compound according to claim 1, wherein ~~any one of claims 1 to 4, characterized in that~~ X is CR^6 ; R^2 , R^3 , R^4 and R^6 are each independently hydrogen, halo, cyano, nitro or hydroxy and R^5 is hydrogen.
6. (Currently Amended) Compound according to claim 1, wherein ~~any one of claims 1 to 5, characterized in that~~ $-a^1=a^2-a^3=a^4-$ is a bivalent radical of formula (a-3) or (a-4) ; $-Z^1-Z^2-$ is a bivalent radical of formula (b-1), (b-2) or (b-3) wherein R^7 is hydrogen or

methyl ; Y is a bivalent radical of formula (c-1) wherein $n = 3$ or (c-2) wherein $m = 0$ or 1 and R^8 is hydrogen ; X is CR^6 ; R^2 , R^3 , R^4 and R^6 are each independently hydrogen, halo, cyano, nitro or hydroxy and R^5 is hydrogen.


7. (Currently Amended) Compound according to claim 1 ~~any one of claims 1 to 6~~ for use as a medicine.
8. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, a therapeutically effective amount of a compound according to claim 1 ~~any one of claims 1 to 6~~.
9. (Currently Amended) The use of a compound according to claim 1, ~~any one of claims 1 to 6 for the preparation of a medicament~~ for the prevention and/or treatment of a disorder or disease responsive to the inhibition of dopamine D_2 , D_3 and/or D_4 -receptors.
10. (Currently Amended) The use of a compound according to claim 1 ~~any one of claims 1 to 6 for the preparation of a medicament~~ for the prevention and/or treatment of a disorder or disease responsive to the inhibition of serotonin reuptake and antagonism of $5-HT_{1A}$ receptors.
11. (Currently Amended) The use of a compound according to claim 1 ~~any one of claims 1 to 6 for the preparation of a medicament~~ for the prevention and/or treatment of a disorder or disease responsive to the combined effect of a dopamine D_2 , D_3 and/or D_4 antagonist, an SSRI and a $5-HT_{1A}$ -agonists, partial agonist or antagonist.
12. (Currently Amended) The use of a compound according to claim 1 ~~any one of claims 1 to 6 for the preparation of a medicament~~ for the prevention and/or treatment of affective disorders such as general anxiety disorder, panic disorder, obsessive compulsive disorder, depression, social phobia and eating disorders ; and other psychiatric disorders such as, but not limited to psychosis and neurological disorders.
13. The use of a compound according to claim 1 ~~any one of claims 1 to 6 for the preparation of a medicament~~ for the prevention and/or treatment of schizophrenia.

14. (Original) Process for the preparation of a compound according to Formula (I) characterized by either


(a) alkylating an intermediate of Formula (II) with an intermediate of Formula (III), wherein all variables are defined as in claim 1 and W is an appropriate leaving group, in a reaction-inert solvent and optionally in the presence of a suitable base ;



(b) reductively aminating an intermediate of Formula (IV) with an intermediate of Formula (III) in a reaction-inert solvent and in the presence of a reducing agent.



(c) reacting an acid chloride of Formula (V) with an intermediate of Formula (III) in a reaction-inert solvent and in the presence of a suitable base, followed by reduction of the corresponding amide intermediate formed in a reaction-inert solvent and in the presence of a reducing agent ;



(d) and, if desired, converting compounds of Formula (I) into each other following art-known transformations, and further, if desired, converting the compounds of Formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms, *N*-oxides thereof and quaternary ammonium salts thereof.